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Control of cellular (de)differentiation in a temporal,
cell-specific, and exchangeable manner is of para-
mount importance in the field of reprogramming.
Here, we have generated and characterized a mouse
strain that allows iPSC generation through the Cre/
loxP conditional and doxycycline/rtTA-controlled
inducible expression of the OSKM reprogramming
factors entirely from within the ROSA26 locus. After
reprogramming, these factors can be replaced by
genes of interest—for example, to enhance lineage-
directed differentiation—with the use of a trap-
coupled RMCE reaction. We show that, similar
to ESCs, Dox-controlled expression of the cardiac
transcriptional regulator Mesp1 together with Wnt
inhibition enhances the generation of functional car-
diomyocytes upon in vitro differentiation of such
RMCE-retargeted iPSCs. This ROSA26-iPSC mouse
model is therefore an excellent tool for studying
both cellular reprogramming and lineage-directed
differentiation factors from the same locus and will
greatly facilitate the identification and ease of func-
tional characterization of the genetic/epigenetic
determinants involved in these complex processes.INTRODUCTION
Pluripotency can be induced in various cell types by the ectopic
expression of four transcription factors Oct4 (also known as
Pou5f1), Sox2, Klf4, and c-Myc (hereinafter referred to as
OSKM), generating induced pluripotent stem cells (iPSCs) (Taka-
hashi and Yamanaka, 2006). Since the initial discovery in 2006,
various methods (Gonza´lez et al., 2011) have been developed
to generate iPSCs using inducible or excisable transposon-
based strategies to control the ectopic expression of the reprog-
ramming factors instead of the more ‘‘classical’’ and uncontrol-Clable retroviral-based systems. The most advanced techniques
in mouse iPSC generation are the recently developed double
transgenic reprogrammable mouse systems (Carey et al.,
2010; Stadtfeld et al., 2010). These doxycycline-inducible
Col1a1 locus-targeted transgenic mouse models allow iPSC
derivation from different cell populations when crossed with
the ubiquitously expressing reverse-tetracycline-dependent-
transactivator (rtTA) ROSA26 mouse strain. However, these
double transgenic approaches lack tissue/cell-specific OSKM
expression, as well as a means of selecting OSKM-expressing
cells, and do not allow the exchange of the reprogramming
factors by other genes to study iPSC lineage-directed differenti-
ation at a well-defined locus. Here, we report a conditional and
inducible (COIN) transgenic mousemodel that allows expression
of OSKM exclusively from within the ROSA26 locus. Moreover,
after reprogramming, the four factors can be replaced in the re-
sulting iPSCs by any cDNA/ORF of interest via a recombinase-
mediated cassette exchange (RMCE) strategy.RESULTS AND DISCUSSION
Generation and Use of the ROSA26-iPSC Mouse Model
to Create Reprogrammed Cells
We generated a COIN OSKM construct by using similar condi-
tional strategies (Belteki et al., 2005), as well as previously pub-
lished (Nyabi et al., 2009) Gateway cloning technologies, and
subsequently targeted this construct to the ROSA26 locus via
homologous recombination in robust hybrid F1 embryonic
stem cells (ESCs), i.e., G4 ESCs (George et al., 2007). In this
double-locked system (Figure 1A and Figure S1A), a loxP-
flanked (floxed) neomycin resistance (NeoR) transcriptional
STOP cassette prevents the expression of the bicistronic rtTA-
IRES-puromycin-pA mRNA and the reprogramming factors.
Through Cre-mediated deletion of this STOP cassette, rtTA is
expressed from the endogenous ROSA26 promoter. Only after
administration of the inducing drug doxycycline (Dox), rtTA will
undergo nuclear translocation and activate the Tet-responsive
element (TRE; tet(o)-CMVmin) that will drive expression of the
polycistronic OSKM cassette along with a reporter geneell Reports 3, 335–341, February 21, 2013 ª2013 The Authors 335
Figure 1. The ROSA26-iPSC Mouse Model
(A) Schematic overview of the conditional and inducible (COIN) OSKM-targeted ROSA26 locus and its use. Cre-mediated removal of the conditional NeoR STOP
cassette leads to ROSA26-based rtTA expression. Inducible expression of the reprogramming factors (OSKM, encoding for the polycistronic Oct4, Sox2, Klf4,
and c-Myc transgene) will only be achieved upon Dox administration and can bemonitored by the inducible EGFP expression. SA, splice acceptor; IRES, internal
ribosome entry site; pA, poly(A) sequence.
(B) Southern blot analysis (50, internal EGFP, and 30 probe) of three correctly targeted ESC clones. wt, wild-type; mut, mutant.
For details, see Figure S1A.(enhanced green fluorescent protein-Luciferase; EGFP-Lucif-
erase). Via diploid embryo aggregation with correctly targeted
ESCs (Figure 1B), a stable mouse line was generated from
several strong, germline-transmitting chimeras (Figures S1B
and S1C). These ROSA26-iPSC mice can be bred to the wide
range of tissue/cell-specific Cre mouse lines available. This
allows conditional and inducible expression of the reprogram-
ming factors in the derived primary cell cultures isolated either
from embryonic or adult offspring for cellular reprogramming
experiments (Figure 2A).
To test our ROSA26-iPSC transgenic model functionally, we
isolated mouse embryonic fibroblasts (MEFs) and adult tail tip
fibroblasts (TTFs) from Sox2 Cre X ROSA26-iPSC mice. We
cultured and expanded these cells under puromycin (Puro)
selection before inducing the reprogramming factors with Dox.
After 3 weeks of continuous Dox induction, several OSKM-
EGFP-expressing colonies with an ESC/iPSC-like morphology
could be detected (Figure 2B). Individual picking and expansion
of these colonies led to the establishment of multiple Dox-inde-
pendent iPSC lines expressing pluripotency-related markers
such as alkaline phosphatase (Alk. Phos.), Oct4, Nanog, and
SSEA1 (Figure 2C) and increased Nanog mRNA expression
levels that are similar to wild-type G4 ESCs (Figure 2D). In vitro336 Cell Reports 3, 335–341, February 21, 2013 ª2013 The Authorsdifferentiation of these iPSCs using embryoid body differentia-
tion assays demonstrated no differences compared to wild-
type ESCs in terms of the formation of embryoid bodies, beating
cardiomyocyes, sprouting vascular endothelial channels, or their
hematopoietic differentiation potential (Figure 2E; data not
shown). To further characterize the differentiation potential of
our iPSC clones in vivo, cells were subcutaneously injected
into immunocompromized nude mice, which led to teratoma
formation for all analyzed clones. Histological analysis of the
tumors demonstrated their differentiation potential toward cell
types of the three different germ layers (Figure 2F). Moreover,
adult iPSC-derived chimeric mice could be generated using
diploid complementation assays, thereby further underscoring
the pluripotent nature of these cells (Figure 2G).
However, as previously reported for other TRE-based trans-
genic mouse lines (Beard et al., 2006; Premsrirut et al., 2011),
we also observed significant mosaic transgene expression in
our ROSA26-iPSC model. Indeed, of our starting fibroblast pop-
ulations, only around 8% of the MEFs (OSKM-heterozygous)
and 16% of the TTFs (OSKM-homozygous) appeared to be
capable of turning on theOSKM-EGFP expression cassette after
2 days of in vitro Dox induction (Figure S2A). As well, when we
turned on the reprogramming factors in vivo for 5 days in
Figure 2. Derivation and Characterization
of ROSA26-iPSC Mouse Model-Derived
iPSCs
(A) The ROSA26-iPSC mouse can be bred to
a tissue/cell-specific Cre mouse line. Isolation of
Cre-excised differentiated cells from hereof-
derived embryonic/adult offspring and subse-
quent Dox administration leads to EGFP-ex-
pressing iPSCs.
(B) Phase contrast and fluorescent picture of an
OSKM-EGFP-expressing MEF-iPSC colony after
3 weeks of continuous Dox induction. Scale bars,
100 mm.
(C) Bright field (Alk. Phos.) and fluorescent pictures
(Oct4, Nanog, and SSEA1) of pluripotency
markers of aMEF-iPSC clone. Scale bars, 100 mm.
(D) qRT-PCR analysis on pluripotency marker
Nanog of wild-type G4 ESCs and MEF-iPSC
clones compared to MEFs.
(E) Graph representing the methylcellulose assay
comparing the hematopoietic cell colonies (BFU-
E, CFU-GM, and CFU-GEMM) after hematopoi-
etic-specific in vitro differentiation of wild-type G4
ESCs versus two MEF-iPSC clones.
(F) An H&E-stained section of aMEF-iPSC-derived
teratoma (endoderm, [EN], ciliated columnar
epithelium with goblet cells; mesoderm [MS],
muscle and ectoderm [EC], squamous epithelium).
Scale bar, 50 mm.
(G) Picture of TTF-iPSC-derived chimeric mice.
(H) Characterization of EC-iPSCs. Scale bars,
200 mm. Error bars represent the SD of the average
of triplicate assays.
See also Figures S2 and S3.a hematopoietic/endothelial lineage-specific manner using Tie2
Cre X ROSA26 OSKM-homozygous mice, we could sort, based
on the EGFP-based transgene expression of our mouse model,
EGFP/c-Kit-positive hematopoietic stem/progenitor cells
(HS/PCs) (Figure S2B) and reprogram them toward iPSCs with
similar characteristics as described before (data not shown).
Therefore, using our model and EGFP-based fluorescence-acti-
vated cell sorting (FACS), it is possible to isolate cells either from
in vivo sources or after in vitro expansion that are still capable of
turning on the OSKM reprogramming factors.
Additionally, it should be noted the reprogramming efficiency
in our developed mouse model is somewhat less efficient in
generating iPSCs (Table S1) than the other two previously pub-
lished Col1a1-based reprogrammable mouse models (Carey
et al., 2010; Stadtfeld et al., 2010). To understand the reason
for this lower efficiency, we directly compared the OSKM
mRNA and protein levels in our ROSA26-iPSC model with those
of the model developed by Carey et al., 2010. Upon Dox admin-
istration, significantly lower mRNA and protein levels of the re-Cell Reports 3, 335–341,programming factors were observed in
OSKM-homozygous, EGFP-positive
sorted MEFs from our ROSA26-based
model compared to OSKM-homozygous
MEFs from the Carey et al., 2010
Col1a1-based model (Figures S2C andS2D). The lower frequencies of reprogramming observed in our
ROSA26-OSKM-based model can therefore be explained by
the overall lower OSKM expression levels. It is interesting that
these differences are less pronounced in our ROSA26-based
TTF-iPSCs that appear to have basal OSKM levels more similar
to wild-type ESCs than in the Col1a1-derived TTF-iPSCs (Fig-
ure S2E). As well, unlike the model published by Stadtfeld et al.
(2010), we see no evidence of spontaneous tumor formation in
adult Sox2 Cre X OSKM-homozygous mice under noninduced
conditions up to 18 months of age. This demonstrates the tight-
ness ofOSKM expression in our system as also shown by quan-
titative real-time PCR (qRT-PCR) analysis of derived MEFs
compared to wild-type MEFs (Figure S2C).
Not only did we obtain fully reprogrammed iPSCs from our
ROSA26-iPSCmodel, but we also generated interesting partially
reprogrammed cells (discussed later) derived from EGFP/CD31-
positive endothelial cells (ECs) (Figure S3A). Upon Dox removal,
these cells have the potential to differentiate spontaneously back
into CD31-positive, vascular-like channels in vitro even withoutFebruary 21, 2013 ª2013 The Authors 337
Figure 3. RMCE Removal of the Reprog-
ramming Factors
(A) Schematic overview of the RMCE strategy to
replace the reprogramming factors by conditional
(pRMCE DV1) or conditional and inducible (pCOIN
DV) incoming vectors.
(B) Using a trap-coupled RMCE reaction,
neomycin-sensitive (NeoS) iPSCs can be effi-
ciently retargeted with pRMCE DV1 or pCOIN
cDNA constructs replacing the reprogramming
factors and restoring NeoR.
(C) Scheme and bright field pictures from X-gal-
stained Cre-excised pRMCE DV1 lacZ-retargeted
TTF-iPSCs and derived E11.5 chimeric embryos.
Scale bar, 200 mm.
(D) Scheme and bright field pictures of noninduced
(Dox) and induced (+Dox) X-gal-stained Cre-
excised, NeoR COIN lacZ-retargeted MEF-iPSC
subclones. Scale bars, 200 mm.the addition of additional cytokines such as VEGF (Figures S3B
and S3C). These cells are somewhat similar to what has recently
been described for rat OSKM-induced vascular progenitor cells
(iVPCs) (Yin et al., 2012) in their ability to differentiate spontane-
ously back into CD31-positive cells whenDoxwas removed from
the system even in late passage (p > 10) clones. Of the three
iVPC clones analyzed in greater detail, all showed discrete pop-
ulations of Alk. Phos.-positive cells (Figure S3D), but only clone 3
was capable of forming a tumor when injected into immunocom-
promised mice. It is interesting that the tumor did not contain
a variety of different tissues derived from all three different
germ layers characteristic for teratomas but instead displayed
a rather limited developmental potential with high vascular
channel formation capacity as judged by CD31 immunostaining
analysis (Figure S3E). By selectively replating clone 3 on to ge-
latinized plates and subcloning ESC-like colonies, we could
derive Dox-independent EC-derived iPSCs (EC-iPSCs) that
ubiquitously expressed ESC cell markers such as Alk. Phos.338 Cell Reports 3, 335–341, February 21, 2013 ª2013 The Authorsand Oct4 (Figure 2H). These reprog-
rammed EC-iPSCs have a greater devel-
opmental potential than the original iVPC
precursor cells and could form teratomas
with all three germ layer derivatives along
with a more limited angiogenic potential
(Figure S3E). Although not ‘‘truly’’ pluripo-
tent, the iVPCs in comparison to EC-
iPSCs can be of great interest in preclin-
ical studies as well as in further unraveling
the molecular mechanisms of cellular re-
programming and identifying genetic
determinants of EC memory. Using this
conditional and inducible ROSA26-iPSC
model system with other tissue/cell-
restricted Cre lines will also enable
researchers to identify other stable
partially reprogrammed cell lines similar
to our mouse iVPCs, partially described
here. This is an important issue as severalconcerns have recently been raised about the genetic stability
(Blasco et al., 2011) and immunogenicity (Zhao et al., 2011) of
true pluripotent iPSCs.
Characterization and Validation of the RMCE
Component of the ROSA26-iPSC Mouse Model in
Lineage-Directed Cellular Differentiation Assays
After successful reprogramming, the ectopic expression of
OSKM is no longer needed and can be shut off by withdrawal
of Dox. However, we designed our construct in such a way
that we can actually use the same ROSA26 locus to remove
and, more important, exchange the reprogramming factors
using a trap-coupled RMCE reaction with high efficiencies as
previously reported (Sandhu et al., 2011). Other cDNAs/ORFs
of interest can hereby be efficiently cloned into Gateway-
compatible vectors and introduced in a conditional (pRMCE
DV1) or conditional and inducible (pCOINDV)manner (Figure 3A).
By cotransfecting such RMCE-compatible incoming vectors
Figure 4. Cardiomyocyte Lineage-Directed
Differentiation of COIN Mesp1-Retargeted
MEF-iPSCs
(A) qRT-PCR analysis of pulsedMesp1 expression
at day 4 of in vitro differentiation in induced, COIN
Mesp1-retargeted MEF-iPSCs compared to non-
induced control cells.
(B) Fluorescent immunohistochemistry pictures
showing TroponinT-positive structures (in red) in
induced and Wnt-inhibited (+Dox/+IWR1) cells at
day 8 of in vitro differentiation. Representative
images for each of the conditions are shown.
Hoechst (blue) DNA staining is monitoring cellu-
larity. Scale bars, 100 mm.
(C) qRT-PCR analysis at day 8 of differentiation on
cardiac marker for Nkx2.5 mRNA levels showing
the increased levels mainly in induced differenti-
ating iPSCs with Wnt inhibition (+Dox/+IWR1).
(D) Beating cardiomyocyte assay showing
the dramatically enhanced differentiation poten-
tial of our COIN Mesp1-retargeted MEF-iPSC
toward beating cardiomyocytes when pulsed
with Mesp1 together with (+Dox/+IWR1) (or
without, +Dox/IWR1) Wnt inhibition compared to
noninduced differentiating cells (Dox/IWR1
and Dox/+IWR1). Error bars represent the (SD of
the average of triplicate assays.together with a FlpE-expressing plasmid, the resulting NeoR
iPSC clones should be correctly retargeted and can, for
example, subsequently be used for lineage-directed differen-
tiation studies (Figure 3B). To demonstrate this, we created
two incoming in vitro Cre-excised lacZ-encoding constructs:
one pRMCE DV1 lacZ construct and one pCOIN DV lacZ
construct. In separate experiments, we successfully replaced
the reprogramming factors by these lacZ constructs. For the
pRMCE DV1 lacZ, we obtained constitutive ROSA26-based
lacZ expression in the retargeted iPSCs (Figure 3C). Using
beta-galactosidase staining analysis, we could show that the
RMCE approach was working at high efficiencies in MEF-
derived (12/12 lacZ-positive/NeoR clones = 100%), TTF-derived
(22/22 lacZ-positive/NeoR clones = 100%), and EC-derived (18/
19 lacZ-positive/NeoR clones = 95%) iPSC clones. The
exchange was further validated using three randomly chosen
NeoR RMCE DV1 lacZ MEF-iPSC clones to demonstrate the
complete removal of the COIN OSKM transgene by genomic
PCR analysis (Figures S4A and S4B). Moreover, high percentage
E11.5 chimeric embryos that constitutively express lacZ could
be derived from retargeted TTF-iPSC clones, thereby demon-
strating that the pluripotency of these cells is not affected after
RMCE with lacZ (Figure 3C). For the pCOIN DV lacZ system,
the expression was, as expected, only induced after Dox supple-
mentation, which once again demonstrates the tight regulation
of this COIN system (Figure 3D).
To functionally test our system further and specifically differ-
entiate our iPSCs toward beating cardiomyocytes as a promising
cell type for preclinical regenerative and tissue repair studies, we
successfully exchanged the OSKM factors in MEF-iPSCs by
a Cre-excised pCOIN DV construct encoding Mesp1, a known
key transcriptional regulator of cardiovascular developmentC(Bondue and Blanpain, 2010). Similar to previously published
results in ESCs (Lindsley et al., 2008), a brief 2-day pulse of
Mesp1 expression in early differentiating iPSCs (Figure 4A),
together with Wnt inhibition (using the Wnt pathway inhibitory
compound IWR1; Chen et al., 2009), preferentially generated
enhanced numbers of cells positive for the definitive cardiac
marker TroponinT (cTnT) (Figure 4B). We also observed signifi-
cantly increased mRNA expression levels of other cardiac
marker genes such as Nkx2.5 as judged by qRT-PCR mRNA
expression analysis (Figure 4C; data not shown) and in the
number of beating cardiomyocytes (Figure 4D; Movies S1
and S2).
We believe that the exchange of the reprogramming factors by
other genes from within the same ROSA26 locus via an efficient
RMCE reaction, together with in vitro validation of the resultant
exchanged iPSC clones, will be of great importance to the field
of cellular (de)differentiation in efficiently identifying genes that
can control cell lineage-directed differentiation. This was
demonstrated by the cardiomyocyte-specific differentiation of
mouse-derived iPSCs by ectopic Mesp1 expression together
with Wnt inhibition. This regulated transgene expression will be
particularly useful in preclinical regenerative medicine
approaches where continued expression of powerful transcrip-
tional modulators may be detrimental for terminal cellular differ-
entiation necessary for tissue repair.
In summary, we have created an in vivo resource that will add
to the toolbox of existing mouse resources that will allow scien-
tists to identify genes more easily and understand their roles in
cellular (de)differentiation processes. It should also be noted
that, given the discovery of the human counterpart of the
ROSA26 locus (Irion et al., 2007) as well as other safe genomic
loci (Hockemeyer et al., 2009), our system could be similarlyell Reports 3, 335–341, February 21, 2013 ª2013 The Authors 339
adapted for human cell-based studies and identifying factors
involved in human ESC/iPSC (de)differentiation.
EXPERIMENTAL PROCEDURES
Generation of the ROSA26-iPSC Mice
The construction of the expression vector, subsequent ESC targeting/
screening, and final generation of ROSA26-iPSC transgenic mice were per-
formed using a similar strategy as described elsewhere (Nyabi et al., 2009).
Briefly, the individual constructs were first created by directional cloning strat-
egies of the specific sequences into Gateway-compatible vectors and subse-
quently recombined using a multisite Gateway LR reaction. PvuI-linearized
DNA of the resulting expression vector was then electroporated into wild-
type G4 ESCs (George et al., 2007) and grown under standard ESC conditions
with G418 selection drug added to the culture medium. Individual G418-resis-
tant ESC colonies were picked, expanded, and screened by PCR and
Southern blot analysis. One of the correctly ROSA26-targeted ESC clones
was subsequently aggregated with diploid E2.5 Swiss embryos and generated
several high-grade, germline-transmitting chimeric animals.
Cellular Reprogramming
(1) Fibroblasts isolated from Sox2 Cre (Lu and Robertson, 2004) X ROSA26-
iPSC E13.5 embryos and tail tips of 6-week-old adult mice were first expanded
under Puro selection before being plated on to culture dishes coated with
a mitomycin C-inactivated feeder layer and reprogrammed in daily refreshed
ESC medium or KSR medium (ESC medium with 15% Knockout Serum
Replacement [Invitrogen] instead of fetal bovine serum) supplemented with
doxycycline hyclate (Dox, 2 mg/ml, Sigma-Aldrich). (2) OSKM-EGFP-express-
ing HS/PCs were isolated from 3-week-old and in vivo Dox-induced (5 days of
daily refreshed Dox in the drinking water, 1 mg/ml) Tie2 Cre (Kisanuki et al.,
2001) X ROSA26-iPSC mice. Cells extracted from the bone marrow or spleen
were first stained with a c-Kit-specific antibody (APC-H7 rat antimouse CD117
[c-Kit], PharMingen) before double EGFP/c-Kit-positive HS/PCs were sorted
on a FACSAria II machine (BD Biosciences) and allowed to reprogram similarly
as described for the fibroblasts. (3) Similarly as for the HS/PCs, ECs were iso-
lated from lungs of 3-week-old and in vivo Dox-induced (5 days of daily re-
freshed Dox in the drinking water, 1 mg/ml) Tie2 Cre (Kisanuki et al., 2001) X
ROSA26-iPSC mice. CD31-positive ECs were isolated using magnetic-acti-
vated cell sorting (MACS) with incubated CD31 (PECAM, rat antimouse
CD31 antibody, BD Biosciences) precoated sheep antirat immunoglobulin G
(IgG) magnetic Dynabeads (Dynal, Life Technologies) and reprogrammed simi-
larly as described for the fibroblasts. Initially, only partially reprogrammed indi-
vidual iVPC colonies could be observed and expanded in the presence of
Dox. Subcloning of one particular iVPC clone on gelatinized plates eventually
led to Dox-independent EC-iPSCs.
Immunohistochemistry
Immunohistochemistry labeling of various different markers were performed
using standard procedures and/or commercially available kits according to
themanufacturer’s instructions: Alk. Phos. (Mouse ESC/iPSCCharacterization
Set [Stemgent] or Leukocyte Alkaline Phosphatase Kit [Sigma-Aldrich]), Oct4
(Mouse ESC/iPSC Characterization Set [Stemgent] or mouse anti-Oct4
primary antibody (Santa Cruz Biotechnology]), Nanog (Mouse ESC/iPSCChar-
acterization Set [Stemgent]), SSEA1 (Mouse ESC/iPSC Characterization Set
[Stemgent]), CD31 (rat anti-CD31 antibody [BD Biosciences]), cTnT (mouse
anti-cTnT antibody [NeoMarkers]) and X-gal (previously described in Novak
et al., 2000).
qRT-PCR
Total RNA was isolated using RNeasy Plus Mini Kit (QIAGEN). cDNA was
synthesized using the First Strand cDNA Synthesis Kit (Roche) with oligo(dT)
primer by starting from equal amounts of RNA as measured by a NanoDrop
spectrophotometer (Thermo Scientific). qRT-PCRs were performed using
the LightCycler 480 SYBR Green I Master (Roche), monitored on a LightCycler
480 system (Roche), and analyzed using qBase software (Hellemans et al.,
2007). Gene expression was standardized against housekeeping genes340 Cell Reports 3, 335–341, February 21, 2013 ª2013 The Authorshydroxymethylbilane synthase (Hmbs), b-actin, and glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh). All primers are listed in Table S2. The error
bars in the graphs (Figures 2D, 4A, 4C, and S2C) represent the SDs of the
average of triplicate reactions (technical replications).
In Vitro Differentiation
(1) Differentiation of ESCs/iPSCs toward hematopoietic cell lineages was per-
formed first by embryoid body (EB) formation in 1% methylcellulose (R&D
Systems) followed by replating and further differentiation in Methocult
GF3434 medium (Stem Cell Technologies) according to the manufacturer’s
instructions. Colonies were blindly scored after 12 days of culture. The error
bars in the graph (Figure 2E) represent the SD of the average of triplicate bio-
logical assays. (2) iPSC differentiation preferentially toward cardiomyocytes
was performed as previously described for ESCs (Lindsley et al., 2008). Early
differentiating iPSC EBs were plated (1.53 105 cells per milliliter) and grown in
bacterial grade Petri dishes in EB differentiation medium and supplemented
with Dox (2 mg/ml) and/or IWR1 (10 mM, Sigma-Aldrich).
Teratoma Formation
iPSCs were trypsinized and subcutaneously injected into the flank of immuno-
compromised nude mice. Forming teratomas were isolated 5 to 8 weeks later
and further processed to paraffin sections stained with hematoxylin and eosin
(H&E) for histological analysis. All experiments performed on mice were
approved by the animal ethical committee of Ghent University.
RMCE Targeting
For the trap-coupled RMCE experiments, Effectene transfection reagent
(QIAGEN) was used according to the manufacturer’s instructions to cotrans-
fect an incoming vector, created via directional cloning steps of individual
Gateway-compatible constructs and subsequently recombined using
Gateway LR reactions as previously described (Nyabi et al., 2009), together
with a FlpE-expressing plasmid (pCAGGS-FlpE-IRES-puromycin-pA) (Schaft
et al., 2001) in a 1:1 ratio into RMCE-compatible iPSCs. G418 selection
(200 mg/ml) was started 48 hr after transfection. After 7 days, individual NeoR
RMCE-retargeted iPSC colonies could be observed and further expanded.
Beating Cardiomyocyte Assay
For each condition, 96 individually plated embryoid bodies were blindly scored
from day 8 until day 12 of differentiation for the presence of beating
cardiomyocytes.
For further details, please see the Extended Experimental Procedures.
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